Bank of America Securities has issued a research report highlighting that Sino Biopharm (01177) has recently completed patient enrollment for the Phase 3 clinical trials of its two drug candidates, TQB2102 and LM302. Notably, LM302 is the first CLDN18.2 antibody-drug conjugate globally to complete patient enrollment for a Phase 3 registrational clinical study, potentially offering a new treatment option for patients. The firm maintains a target price of HK$8.6 and reiterates its "Buy" rating on the stock.